{"id":207721,"date":"2025-03-03T21:13:55","date_gmt":"2025-03-04T03:13:55","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/03\/differential-protection-against-sars-cov-2-reinfection-pre-and-post-omicron"},"modified":"2025-03-03T21:13:55","modified_gmt":"2025-03-04T03:13:55","slug":"differential-protection-against-sars-cov-2-reinfection-pre-and-post-omicron","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/03\/differential-protection-against-sars-cov-2-reinfection-pre-and-post-omicron","title":{"rendered":"Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/differential-protection-against-sars-cov-2-reinfection-pre-and-post-omicron.jpg\"><\/a><\/p>\n<p>The results show two distinct patterns in the protective effect of natural infection against reinfection in the Omicron era compared to the pre-Omicron era. Before the emergence of Omicron, natural infection offered robust protection against reinfection, with roughly 80% effectiveness and minimal signs of waning over time after the infection. However, during the Omicron era, this protection was strong only for recently infected individuals, rapidly declining over time after the infection and ultimately diminishing within a year. These patterns were consistent regardless of whether any infection or only symptomatic infection was considered as an outcome, and for both vaccinated and unvaccinated populations.<\/p>\n<p>The two distinct patterns observed in the Omicron versus pre-Omicron eras provide population-level results that validate previous experimental molecular evidence<sup><a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 1\" title=\"Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21361&ndash;379 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR1\" id=\"ref-link-section-d56746198e4357\">1<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 2\" title=\"Roemer, C. et al. SARS-CoV-2 evolution in the omicron era. Nat. Microbiol. 8, 1952&ndash;1959 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR2\" id=\"ref-link-section-d56746198e4360\">2<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Bouhaddou, M. et al. SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Cell 186, 4597&ndash;4614 e4526 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9?linkId=12823150#ref-CR18\" id=\"ref-link-section-d56746198e4363\">18<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21162&ndash;177 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9?linkId=12823150#ref-CR19\" id=\"ref-link-section-d56746198e4363_1\">19<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 20\" title=\"Willett, B. J. et al. SARS-CoV-2 omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161&ndash;1179 (2022).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR20\" id=\"ref-link-section-d56746198e4366\">20<\/a><\/sup>, and are probably the result of a complex interplay of several interrelated factors, in addition to waning immunity, immune evasion and the accelerated and convergent evolution of Omicron, such as immune imprinting, varying immunogenicity, global population immunity faced by the strains and population characteristics associated with infections at different stages of the pandemic.<\/p>\n<p>Whereas these factors are interconnected and challenging to disentangle, the observed differences in protection against reinfection may stem from distinct evolutionary pressures acting on SARS-CoV-2 during the pre-Omicron and Omicron eras. In the pre-Omicron era, with a large proportion of individuals remaining immune naive because of non-pharmaceutical interventions and delayed scale-up of vaccination, intrinsic transmissibility may have been the primary driver of viral adaptation. This was evidenced by the emergence of more transmissible variants such as Alpha<sup><a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 4\" title=\"Abu-Raddad, L. J. et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. PLoS Med. 18, e1003879 (2021).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR4\" id=\"ref-link-section-d56746198e4373\">4<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 22\" title=\"du Plessis, L. et al. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. Science 371708&ndash;712 (2021).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR22\" id=\"ref-link-section-d56746198e4376\">22<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 23\" title=\"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https:\/\/doi.org\/10.1126\/science.abg3055 (2021).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR23\" id=\"ref-link-section-d56746198e4379\">23<\/a><\/sup> and Delta<sup><a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 24\" title=\"Luo, C. H. et al. Infection with the SARS-CoV-2 delta variant is associated with higher recovery of infectious virus compared to the alpha variant in both unvaccinated and vaccinated individuals. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab986 (2021).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR24\" id=\"ref-link-section-d56746198e4383\">24<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 25\" title=\"Qassim, S. H. et al. Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections. Front. Immunol. 13, 984784 (2022).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR25\" id=\"ref-link-section-d56746198e4386\">25<\/a><\/sup>. Conversely, following the very large and widespread Omicron wave in early 2022 (Extended Data Fig. <a data-track=\"click\" data-track-label=\"link\" data-track-action=\"figure anchor\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#Fig4\">3<\/a>)<sup><a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 26\" title=\"Chemaitelly, H. et al. Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar. BMJ Public Health 1, e000479 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR26\" id=\"ref-link-section-d56746198e4393\">26<\/a><\/sup>, most individuals possessed some level of immunity, either from infection or vaccination. This may have shifted the dominant evolutionary pressure towards immune escape through not only antigenic drift, but also recombination and convergent evolution as the adaptive mechanisms for the virus<sup><a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 2\" title=\"Roemer, C. et al. SARS-CoV-2 evolution in the omicron era. Nat. Microbiol. 8, 1952&ndash;1959 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR2\" id=\"ref-link-section-d56746198e4397\">2<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 18\" title=\"Bouhaddou, M. et al. SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Cell 186, 4597&ndash;4614 e4526 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR18\" id=\"ref-link-section-d56746198e4400\">18<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 27\" title=\"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614521&ndash;529 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR27\" id=\"ref-link-section-d56746198e4403\">27<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 28\" title=\"Ito, J. et al. Convergent evolution of SARS-CoV-2 omicron subvariants leading to the emergence of BQ.1.1 variant. Nat. Commun. 14, 2671 (2023).\" href=\"https:\/\/www.nature.com\/articles\/s41586-024-08511-9#ref-CR28\" id=\"ref-link-section-d56746198e4406\">28<\/a><\/sup>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The results show two distinct patterns in the protective effect of natural infection against reinfection in the Omicron era compared to the pre-Omicron era. Before the emergence of Omicron, natural infection offered robust protection against reinfection, with roughly 80% effectiveness and minimal signs of waning over time after the infection. However, during the Omicron era, [\u2026]<\/p>\n","protected":false},"author":709,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,385],"tags":[],"class_list":["post-207721","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-evolution"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/207721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/709"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=207721"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/207721\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=207721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=207721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=207721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}